泰格医药(03347)于2026年6月16日发布公告，披露当日于深圳证券交易所回购3,411,400股A股普通股，约占回购前公司已发行股本的0.3454%。本次回购价格区间介乎人民币38.66元/股至人民币39.78元/股，合计耗资约人民币1.33亿元（对应人民币133,443,661.44元）。
公告显示，截至2026年6月15日，公司已发行股本（不含库藏股）共717,645,592股，库藏股为20,255,658股，总股本为737,901,250股。完成本次回购后，截至2026年6月16日，公司已发行股本（不含库藏股）减少至714,234,192股，库藏股增加至23,667,058股，总股本仍为737,901,250股。
公司确认，本次回购依据相关上市规则及当地适用法规进行，并严格遵守了有关法律法规和监管要求。上述公告由公司董事叶小平签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.